<DOC>
	<DOCNO>NCT02274558</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability NBI-98854 administer daily treatment Tardive Dyskinesia ( TD ) symptom .</brief_summary>
	<brief_title>A Phase 3 Study NBI-98854 Treatment Tardive Dyskinesia</brief_title>
	<detailed_description>This Phase 3 , randomize , double-blind , placebo-controlled , parallel , fixed-dose study evaluate efficacy , safety , tolerability two dose NBI-98854 ( 40 mg 80 mg ) compare placebo , administer daily . The study design include double-blind , placebo-controlled treatment period 6 week double-blind NBI-98854 treatment period additional 42 week , total 48 week treatment . Final follow-up assessment conduct 4 week last dose study drug .</detailed_description>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<criteria>1 . Subjects childbearing potential must agree use hormonal two form nonhormonal contraception ( dual contraception ) consistently screen , treatment followup period study . 2 . Female subject must pregnant . 3 . Have one follow clinical diagnosis least 3 month prior screen : Schizophrenia Schizoaffective Disorder , Mood Disorder . 4 . Have clinical diagnosis neurolepticinduced TD least 3 month prior screen . 5 . Have moderate severe TD . 6 . If use maintenance medication ( ) schizophrenia schizoaffective disorder , mood disorder , stable dos . 7 . Be good general health . 8 . Have adequate hearing , vision , language skill perform procedure specify protocol . 9 . Have negative drug screen amphetamine , barbiturate , benzodiazepine , phencyclidine , cocaine , opiates , cannabinoids 1 . Have active , clinically significant unstable medical condition within 1 month prior screen . 2 . Have know history substance dependence , substance ( drug ) alcohol abuse 3 . Have significant risk suicidal violent behavior . 4 . Have know history neuroleptic malignant syndrome . 5 . Have know history long QT syndrome cardiac tachyarrhythmia . 6 . Have cancer diagnosis within 3 year screen ( exception allow ) 7 . Have receive investigational drug within 30 day prior screen plan use investigational drug ( NBI98854 ) study . 8 . Have blood loss â‰¥550 mL donate blood within 30 day prior Baseline . 9 . Have allergy , hypersensitivity , intolerance tetrabenazine . 10 . Have previous exposure NBI98854 previously participate NBI98854 clinical study . 11 . Are currently pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>